Skip to main content

agilon health, inc.

AGL
Exchange
NYSE
Industry
Services-Misc Health & Allied Services, NEC
SEC CIK
0001831097

No open-market purchases or sales by agilon health, inc. insiders were filed in the last 90 days; 179 institutions reported holding it in 13F filings for Q2 2026, worth $1.73B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 13, 2026
$1.94B
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +83 vs. previous quarter
179
13F valueReported value at the end of Q2 2026
$1.73B
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$5.93B
−2.1% year over year
Net income, FY2025
-$391.3M
No comparable prior period
Free cash flow, FY2025
-$119.0M
No comparable prior period
Revenue, Q3 FY2026
$1.52B
+5.9% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $391.3M (6.6% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
846.7K
Shares sold short
Change
−52.4K
−5.8% vs. previous
Days to cover
4.71
At average daily volume

Superinvestors holding AGL, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding AGL at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by agilon health, inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 11, 2026 (view filing)Mar 92 daysZamore DeniseChief Legal OfficerPPurchase+5.54K––+1.2%448.7K after
Mar 11, 2026 (view filing)Mar 92 daysVenkatachaliah GirishChief Technology OfficerPPurchase+18.4K––+6.9%285.1K after
Mar 11, 2026 (view filing)Mar 92 daysShaker BenjaminChief Markets OfficerPPurchase+18.4K––+1.3%1.39M after
Mar 3, 2026 (view filing)Mar 21 dayShaker BenjaminChief Markets OfficerPPurchase+500.0K$0.60+$300.0K+57.6%1.37M after
Jan 30, 2026 (view filing)Nov 12, 202579 daysLateWulf John WilliamDirectorPPurchase+81.0K$0.63+$51.0K+28.4%365.9K after
Apr 3, 2025 (view filing)Nov 29, 2023491 daysSchwaneke Jeffrey A.Chief Financial OfficerPPurchase+22.3K$11.22+$250.2KNew position22.3K afterAmended
Mar 18, 2025 (view filing)Mar 144 daysSell StevenCEO & PresidentPPurchase+42.4K––+12.9%370.9K after
Mar 18, 2025 (view filing)Mar 144 daysShaker BenjaminChief Markets OfficerPPurchase+11.8K––+2.6%461.2K after
Mar 18, 2025 (view filing)Mar 144 daysVenkatachaliah GirishChief Technology OfficerPPurchase+9.43K––+6.3%158.4K after
Dec 13, 2024 (view filing)Dec 13Same dayMcLoughlin KarenDirectorPPurchase+25.0K$2.20+$55.0K+51.9%73.2K after

Top 10 13F holders, Q2 2026

See all 179 holders

The largest institutional positions in agilon health, inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding AGL in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Clayton, Dubilier & Rice, LLC4,000,000$428.7M47.90%00.0%Unchanged
Morgan Stanley2,011,196$215.6M0.01%−88,255−4.2%Reduced
North Peak Capital Management, LLC1,485,066$159.2M17.69%−60,471−3.9%Reduced
BlackRock, Inc.1,146,520$122.9M0.00%+273,356+31.3%Added
AQR Capital Management LLC692,541$74.2M0.03%−282,356−29.0%Reduced
Goldman Sachs Group Inc686,792$73.6M0.01%−375,444−35.3%Reduced
Vanguard Capital Management LLC525,328$56.3M0.00%−13,208−2.5%Reduced
Marshall Wace, LLP468,293$50.2M0.04%+468,293New
Durable Capital Partners LP440,642$47.2M0.46%+440,642New
D. E. Shaw & Co., Inc.390,149$41.8M0.03%−352,069−47.4%Reduced

Holders of 5% or more of AGL

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of agilon health, inc..

Largest holders of AGL from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Morgan Stanley13G/A12.20%50.2M shares–Jan 7, 20226 filingsMay 5, 2025SEC
North Peak Capital Management, LLC13G/A9.50%39.4M shares+4.30 ppfrom 5.20%Aug 29, 20252 filingsNov 13, 2025SEC